(Q24248657)

6 August 2017

0 references

1 reference

title

Sublingual immunotherapy for allergic rhinitis (English)

1 reference

6 August 2017

1 reference

1 reference

3

Stephen Durham

0 references

Stephen R Durham

3

object named as

S R Durham

1 reference

6 August 2017

Duncan Wilson

1

0 references

Marcia Torres-Lima

2

0 references

D R Wilson

1

1 reference

PubMed ID

6 August 2017

L I Torres

2

1 reference

6 August 2017

22 April 2003

0 references

1 January 2003

1 reference

Cochrane Database of Systematic Reviews

6 August 2017

1 reference

6 August 2017

CD002893

1 reference

6 August 2017

2

1 reference

Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study.

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

[Sublingual immunotherapy with cat epithelial extract. Personal experience]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893

7 January 2021

10.1002/14651858.CD002893

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

4253374

PubMed ID

6 August 2017

4253374

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference

4253374

1 reference

PubMed ID